Secondary Osteosarcoma Treatment in Israel

Osteosarcoma can be delineated into “primary” and “secondary” categories. While primary osteosarcoma is not directly associated with another cancer, disease, or treatment, secondary osteosarcoma develops in connection with a pre-existing skeletal disease, cancer, or previous treatments such as irradiation and chemotherapy. Primary osteosarcoma typically occurs in young patients (10-20 years old) corresponding with the period of bone growth in adolescence. In contrast, secondary osteosarcoma usually occurs in the elderly.

The malignancy can be further categorized into central tumors and surface tumors, each with different subtypes. The type and subtype of osteosarcoma are determined by looking at the tumor cells through a microscope. The most common subtype is called conventional central osteosarcoma (or in short, conventional osteosarcoma). The other subtypes are much less common, as each accounts for less than 5% of all osteosarcomas.

Surgery often constitutes the first line of treatment for secondary osteosarcoma treatment in Israel, yet inadequate surgical excision is a common problem.

Robotic surgery, or robot-assisted surgery, allows doctors to perform complex minimally invasive surgical procedures with precision and accuracy through the use of robotic arms. These arms are controlled by the surgeon through a dedicated console.

Widely accepted as one of the most advanced surgical systems available, the new da Vinci Xi represents the 4th generation of surgical robotic technology, taking surgical treatment to an entirely new level. The da Vinci Xi features 3D high-definition visualization that provides the clearest possible view of the surgical site, a greatly expanded range of motion, and improved manipulator capabilities. Additional features include a tremor filtration system which eliminates natural hand tremors and significantly enhances surgical precision.

Greatly contributing to the precise detection and removal of tumors, advanced surgical robotic systems, such as the da Vinci Xi, offer many cancer patients a new hope for a full, healthy life.

At Sheba Medical Center, we are proud to stand at the forefront of surgical innovation and operate many advanced robotic systems, including the da Vinci Xi.

Having discovered a few of the many advantages of receiving secondary osteosarcoma treatment in Israel, where exactly should you pursue it? Sheba Medical Center is an exceptional choice. One of the 10 best hospitals in the world according to Newsweek magazine, Sheba is dedicated to providing patients with world-class medical care.

The advantages of receiving treatment at Sheba Medical Center include:

• Antiangiogenesis: Antiangiogenesis is a breakthrough treatment for metastatic sarcoma, which inhibits the development of blood vessels that feed metastases. Research trials showed that in 46% of the patients who received the therapy, the enlargement of 31% of the metastases was stopped.
• As a government institution, we have no hidden costs, and our fees are transparent. Although we offer advanced treatments that are available only in select medical institutions around the world, our prices are affordable.
• Sheba treats each patient as a unique individual, personalizing every therapy program.
• Sheba’s 360-degree care approach to every patient, which means that Sheba’s professionals will assist you with arranging medical record reviews, travel, visas, accommodations, and language interpretation as needed.
• Sheba has full accreditation from the Joint Commission International (JCI), the premier international healthcare accrediting group.
• Sheba has both advanced treatment and laboratory facilities. At Sheba, patients receive every aspect of their treatment in a single facility.
• Our physicians are actively involved in the latest research and application of progressive treatments.